Biomedical company Femasys, Inc. (FEMY) announced on Monday that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for FemChec. This innovative diagnostic solution is designed to check the fallopian tubes through controlled delivery of contrast to confirm tubal status.
Besides attaining 510(k) clearance, FemChec, a product that generates contrast, plays a crucial role in the confirmation test following the administration of FemBloc, a non-surgical permanent birth control method currently in late-stage pivotal trials.
